Our pipeline has been built upon our deep knowledge in small molecules that restore cellular homeostasis and health.  Focusing on diseases that are marked by cell dysfunction and loss, our candidate portfolio comprises molecules that modulate novel targets and have shown proof of concept in accepted models of disease.

Our programs are at various stages of development, and we foresee the selection of IND candidates for some programs within the next several months.